Biopharmaceutical firm Merck has announced that it has entered into a definitive agreement to purchase Pandion Therapeutics through a subsidiary, for a total equity value of about $1.85m. The post Merck signs agreement to purchase Pandion Therapeutics appeared first on Pharmaceutical Business review. … [Read more...]

Belgium-based biopharmaceutical firm UCB has expanded its collaboration with technology company Microsoft to accelerate discovery and development of drugs for people living with severe diseases in immunology and The post UCB expands partnership with Microsoft to speed up drug development appeared first on Pharmaceutical Business review. … [Read more...]

Specialist HIV company ViiV Healthcare has submitted a supplemental new drug application (sNDA) to the US Food and Drug Administration (FDA) to expand the use of Cabenuva. Cabenuva The post ViiV Healthcare seeks USFDA approval to expand Cabenuva use for HIV-1 infected adults appeared first on Pharmaceutical Business review. … [Read more...]

Pharmaceutical company Pfizer has announced that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for priority review for TicoVac, a tick-borne encephalitis The post USFDA accepts priority review for Pfizer’s TicoVac appeared first on Pharmaceutical Business review. … [Read more...]

AstraZeneca has voluntarily withdrawn the Imfinzi (durvalumab) indication for adult patients who received treatment earlier in the US for locally advanced or metastatic bladder cancer. The company has The post AstraZeneca withdraws Imfinzi indication in US for bladder cancer appeared first on Pharmaceutical Business review. … [Read more...]